Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A

Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A

SSSE:603207
21.59
CNY
-0.09
(-0.42%)
1.20EPS
20.31P/E
3.96BMarket Cap
Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A
SSE:603207
(Shanghai Stock Exchange)

Recent

price

21.59

P/E

ratio

20.31

div

yld

4.39%

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.12
2.26
3.34
3.81
3.94
3.54
3.27
3.45
Revenue per Share
0.89
1
1.05
1.46
1.7
1.53
1.29
1.2
Basic EPS, GAAP
0.92
0.87
1.39
0.63
1
0.96
0.66
- -
Free Cash Flow per Basic Share
1.41
0.86
0.7
0.93
- -
- -
2.2
0.95
Dividend per Share
1.61
1.8
1.91
3.1
4.83
7.71
6.81
7
Book Value per Share
1.61
1.54
1.67
2.87
4.62
7.56
6.66
6.87
Tangible Book Value per Share
160
160
120
120
120
134
161
160
Basic Weighted Avg Shares
340
361
402
457
472
475
525
554
Sales/Revenue/Turnover
48.99
50.6
37.59
44.71
49.32
49.33
45.76
39.48
Operating Margin (%)
3
4
4
4
3
3
3
- -
Depreciation Expense
142
160
126
175
204
205
207
193
Net Income, GAAP
13.99
14.42
18.3
14.99
14.14
14.29
13.99
13.5
Effective Tax Rate (%)
41.8
44.27
31.43
38.34
43.15
43.25
39.5
34.87
Profit Margin (%)
180
162
171
238
320
864
714
728
Working Capital
- -
- -
1
1
- -
- -
- -
- -
LT Debt
193
216
229
372
580
1,234
1,093
1,133
Total Equity
- -
71.85
52.77
55.98
42.1
22.54
17.76
16.91
Return on Invested Capital (%)
- -
78.09
56.64
58
42.68
22.59
17.8
17.13
Return on Capital (%)
- -
78.21
56.79
58.25
42.76
22.63
17.83
17.18
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8
9
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
161
161
162
Market Capitalization
4,427
3,593
3,957

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
883
905
902
Cash, Cash Equivalents & STI
646
675
721
Accounts Receivable, Net
129
119
102
Inventories
61
61
57
Total Current Liabilities
111
163
174
Payables & Accruals
- -
- -
- -
ST Debt
8
9
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
45.18%
-11.46%
Free Cash Flow
- -
2.92%
-16.93%
Net Income, GAAP
- -
7.16%
1.08%
Sales/Revenue/Turnover
- -
7.89%
10.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
125
137
105
107
475
2025
129
141
- -
128
525
2026
146
136
144
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.42
0.27
0.27
1.53
2025
0.37
0.38
- -
0.23
1.29
2026
0.35
0.31
0.31
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
0.7
2.2
2026
- -
- -
0.25
- -
- -
Business
Shanghai Xiao Fang Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise that specializes in the research, development, manufacturing, and commercialization of over-the-counter (OTC) external-use pharmaceuticals, topical dermatological treatments, and consumer healthcare products. Founded in 1993 as Shanghai Yunjia Huangpu Pharmaceutical Co., Ltd. and headquartered in Shanghai, China, the company operates across three core business segments: Gastrointestinal and Laxative Preparations, which includes Kaiselu (glycerin enema), glycerin enema solutions, and liquid paraffin for pediatric, adult, and geriatric constipation relief; Dermatological and Topical Formulations, marketed predominantly under its flagship Xinlong brand, comprising calamine lotion, zinc oxide ointment, Xinlong Hongtun diaper rash ointment, sulfur ointment, salicylic acid ointment, boric acid solution, urea cream, hydrocortisone butyrate cream, compound benzoic acid tincture, and povidone-iodine disinfectant solutions; and ENT and Oral Care Preparations, featuring phenol glycerin ear drops, sodium bicarbonate ear drops, Longyidian oral ulcer topical treatments, and Xiaofang Hanhan pharyngitis gargle and mouthwash solutions. Shanghai Xiao Fang Pharmaceutical Co., Ltd. serves retail consumers, community clinics, and hospital outpatient departments throughout mainland China via an extensive distribution network of retail pharmacy chains, regional pharmaceutical wholesalers, and major e-commerce healthcare platforms. In August 2024, the company achieved a major corporate milestone by completing its initial public offering (IPO) and listing its Class A shares on the Main Board of the Shanghai Stock Exchange under the ticker symbol 603207, raising approximately RMB 498.8 million in gross proceeds. Following its listing, the company has actively deployed IPO proceeds into strategic capital expansion initiatives, including the construction of a modern automated topical pharmaceutical production base in Shanghai to expand manufacturing capacity, the establishment of an advanced research and development center targeting innovative traditional Chinese medicines and specialized topical delivery systems, and the nationwide enhancement of its omnichannel retail marketing infrastructure.